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ABSTRACT
HIV-1 is able to elicit broadly potent neutralizing antibodies in a very small subset of individuals only after several years of
infection, and therefore, vaccines that elicit these types of antibodies have been difficult to design. The RV144 trial showed
that moderate protection is possible and that this protection may correlate with antibody-dependent cellular cytotoxicity
(ADCC) activity. Our previous studies demonstrated that in an HIV vaccine phase I trial, the DP6-001 trial, a polyvalent Env
DNA prime-protein boost formulation could elicit potent and broadly reactive, gp120-specific antibodies with positive neutral-
ization activities. Here we report on the production and analysis of HIV-1 Env-specific humanmonoclonal antibodies (hMAbs)
isolated from vaccinees in the DP6-001 trial. For this initial report, 13 hMAbs from four vaccinees in the DP6-001 trial showed
broad binding to gp120 proteins of diverse subtypes both autologous and heterologous to vaccine immunogens. Equally cross-
reactive Fc receptor-mediated functional activities, including ADCC and antibody-dependent cellular phagocytosis (ADCP) ac-
tivities, were present with both immune sera and isolatedMAbs, confirming the induction of nonneutralizing functional hMAbs
by the DNA prime-protein boost vaccination. Elicitation of broadly reactive hMAbs by vaccination in healthy human volunteers
confirms the value of the polyvalent formulation in this HIV vaccine design.
IMPORTANCE
The roles of Fc receptor-mediated protective antibody responses are gaining more attention due to their potential contribution
to the low-level protection against HIV-1 infection that they provided in the RV144 trial. At the same time, information about
hMabs from other humanHIV vaccine studies is very limited. In the current study, both immune sera andmonoclonal antibod-
ies from vaccinated humans showed not only high-level ADCC and ADCP activities but also cross-subtype ADCC and ADCP
activities when a polyvalent DNA prime-protein boost vaccine formulation was used.
One important finding from the RV144 ALVAC-HIV(vCP1521) prime-AIDSVAX B/E boost vaccine efficacy trial
is the identification of immune correlates of vaccine-induced pro-
tection from acquisition of human immunodeficiency virus type 1
(HIV-1). The presence of antibodies targeting the Env gp120
V1/V2 region was inversely correlated with infection risk, while
the presence of IgA Env-binding antibodies directly correlated
with infection risk (1). Further studies indicated that the presence
of low plasma IgA Env antibody levels in association with high
levels of antibody-dependent cellular cytotoxicity (ADCC) was
inversely correlated with infection (1).
While broadly neutralizing antibodies (bnAbs) have been the
main focus in HIV vaccine development efforts for several de-
cades, ADCCactivities have also been suggested in the literature to
play important roles in the control of established HIV-1 infection
as well as protection from initial infection (2). The majority of
such studies have shown an inverse correlation between ADCC
and the progression of disease or viral load (2). There was an
inverse correlation between titers of ADCC activity in milk and
transmission to newborns which was not correlated with neutral-
ization (3).
Along with ADCC, an inverse correlation exists between anti-
body-dependent cell-mediated viral inhibition (ADCVI) and pro-
gression to simian AIDS (4). Furthermore, phagocytosis is in-
creased in acute infection and is impaired in chronic infection for
monocytes and dendritic cells. Blockage of Fc gamma receptor II
(FcRII) results in the loss of antibody-dependent cellular phago-
cytosis (ADCP) activity (5). It was shown in a mucosal protection
study in a nonhuman primate (NHP)model that nonneutralizing
antibodies can reduce the plasma viral load, and phagocytosis was
implicated in passive protection (6).
When investigating how well an adenovirus prime-gp140
boost vaccination regimen compared to anunboosted vaccination
in macaques, it was discovered that improved ADCC and ADCVI
levels correlated with reduced acute viremia (7). Animals that had
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greater prechallenge ADCC, ADCVI, and transcytosis inhibitory
activities had greater antibody avidity and reduced acute viremia
(7). In humans, differences in vaccination efficacy may have been
due to the Fc-mediated functions elicited by each vaccine. The
RV144 trial had an immunogen similar to that in the VAX003
trial, yet the outcomes were different. The RV144 vaccine was able
to elicit highly functional IgG3 antibodies, while the repeated im-
munization of a subunit vaccine pushed the VAX003 vaccine rep-
ertoire only into the less functional IgG4 subclass (8). Mounting
evidence indicates that more complex interrogations of serology
are needed to understand vaccine trial outcomes and that these
interrogations include Fc-mediated activities (9).
In recent years, molecularly cloned human monoclonal anti-
bodies (hMAbs) from HIV-1-infected patients have been used to
provide a more in-depth understanding of monoclonal antibody
(MAb)-mediated ADCC activity. However, there are only a few
humanMAbs that have been demonstrated to have potent ADCC
activities. MAb A32 is a nonneutralizing antibody isolated from a
chronically infected individual that has been shown to bind to
Env on the surface of CD4 cells and mediate potent ADCC
activity. Most importantly, an A32 Fab fragment can block most
of the ADCC activity in a broad range of HIV-infected plasma
samples (10). Two A32-like MAbs with distinct ADCC potencies
were shown to have overlapping epitopes but differed in their
binding angle and ability tomediate ADCC (11). Nonneutralizing
epitopes are usually buried on the trimer surface and accessible
only after engagement by CD4, which is the case with the Fc-
mediated function of MAb A32 (10).
There is only limited study with ADCC-mediating MAbs pro-
duced from human volunteers who received experimental HIV
vaccines, and theseMAbswere almost exclusively from the RV144
trial. In the present study, we assessed the Fc-mediated effector
functions of a panel of HIV-1 Env-specific MAbs isolated from
four volunteers who received a DNA prime-protein boost human
vaccine in a previously reported phase I clinical trial, the DP6-001
trial (12). These MAbs could recognize a wide range of primary
HIV-1 Env glycoproteins from multiple major subtypes. While
these MAbs did not exhibit significant neutralizing activity, they
demonstrated potent Fc-mediated effector functions, including
ADCC and ADCP activities. Our results provide valuable infor-
mation on the magnitude and quality of ADCC activities medi-
ated by MAbs produced from the second human HIV-1 vaccine
trial, in addition to the RV144 trial. The information learned here
FIG 1 Serum antibody responses from subjects in the DP6-001 phase 1 vaccine trial. (A) gp120-specific IgG titers for select volunteers. The gp120 protein used
to coat the ELISA plates for detection of the IgG titer was a proportionally mixed solution of the 5 autologous gp120s used in the DP6-001 immunization. Solid
arrows, immunizationwithDNAprime; open arrows, immunizationwith gp120 protein boosts. In groupA (GrpA), theDNAprimewas done i.d., while in group
B (GrpB) and group C (GrpC), the DNA prime was done i.m. The volunteer in group C received a high-dose DNA prime and received only the first boost. (B)
Serum neutralization titers (ID50) determined by the PhenoSense assay at Monogram Biosciences. NA, not available; -, no detectable titer.
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can be used as a baseline to guide the design of future HIV-1
vaccines to elicit high-level, broadly reactive Fc-mediated effector
functions.
MATERIALS AND METHODS
Plasma and PBMC samples from DP6-001 vaccine recipients. All par-
ticipants in the completed multigene polyvalent HIV vaccine DP6-001
phase I clinical trial gave written informed consent, as previously de-
scribed (12). Samples were collected and tested according to protocols
approved by the institutional review board (IRB) at the University of
Massachusetts Medical School.
Plasma and peripheral blood mononuclear cell (PBMC) samples in-
volved in the current study were from subjects ABL-034 (group A), ABL-
001 and ABL-003 (group B), and ABL-040 (group C). The selection of
sampleswas random in this pilot study, but sampleswere collected fromat
least one volunteer from each of the three study groups in which the
dosing and route of DNA prime immunization were tested. The plasma
samples used for ADCP assays were collected at week 0 (prebleed) and
week 30 (post-protein boosts). The PBMCs used for Env-specific MAb
isolation were collected from subjects ABL-001, ABL-003, and ABL-034
after two protein boosts and from subject ABL-040 after one protein boost
due to the early termination of group C after one protein boost (13).
Isolation of Env-specific single B cells. The cryopreserved PBMCs
from the above-described vaccinees were thawed and processed in two
ways for gp120-specific single B cell sorting. In the first method, freshly
thawed PMBCs were cultured in RPMI 1640 with 15% fetal bovine serum
(FBS), 1% L-glutamine, and 1% penicillin-streptomycin (P/S) overnight
at 37°C with 5% CO2. Then, B cells were isolated by magnetic bead sepa-
ration (magnetically activated cell sorting human B cell isolation kit II;
Miltenyi Biotec, San Diego, CA). The gp120 protein probe for antigen-
specific B cell staining was a mixture of 5 gp120 proteins from HIV-1
strains A2 (clade A strain 92UG037.8), Bal and B (clade B strains Bal and
92US715.6, respectively), Czm (clade C strain 96ZM651), and AE (clade
AE strain 93TH976.17), which were autologous to gp120 DNA and pro-
teins in the DP6-001 vaccine formulation. The B cells were stained with
phycoerythrin (PE)-conjugated gp120 protein, anti-human-CD19 allo-
phycocyanin (APC)-Cy7, and Via-Probe solution (a dead cell marker)
(BD Biosciences, San Jose, CA). gp120-positive, CD19, and 7-amino-
actinomycinD-negative cells were sortedwith a FACSAria flow cytometer
(BD) into 96-well PCR plates containing a lysis buffer (RNaseOut recom-
binant ribonuclease inhibitor, Invitrogen 5 first-strand buffer, dithio-
threitol, Igepal detergent). The plates were immediately spun down and
frozen on dry ice.
The second method involved bulk sorted B cells isolated from freshly
thawed volunteer PBMCs. After B cell isolation, the cells were incubated
with PE-conjugated gp120 and cell markers as described above. The cells
were then sorted into a single tube by use of the FACSAria flow cytometer
under the same conditions described above. Sorted cells were then seeded
at clonal dilutions in 96-well round-bottom culture plates with 5  104
irradiated EL4C5 feeder cells, medium B (RMPI 1640, 15% FBS, 2%
HEPES, 0.1% 2-mercaptoethanol, 1% P/S), and 3% activated rabbit spleno-
cyte supernatant. After a week of culture, the supernatants were tested for
gp120 binding by enzyme-linked immunosorbent assay (ELISA), and the
cells in the gp120-positive wells were harvested for cloning of Ig variable
regions.
Isolation ofV(D)J immunoglobulin regions.The single B cells sorted
into PCR plates were directly amplified by reverse transcription (RT) and
nested PCR of the variable Ig region. In contrast, for the wells from the
clonal culture positive for gp120 binding, RNAwas extracted for RT-PCR.
The Ig heavy chain-variable (VH), and lambda light chain-variable (VL),
or kappa light chain-variable (VK) regionswere isolated byRT-PCRusing
the RT and nested PCR primers described in a previous report (14).
RT was performed using SuperScript III reverse transcriptase (Invit-
rogen) according to themanufacturer’s instructions, with primer concen-
trations of 10 M being used for each heavy chain primer and 25 M
being used for each light chain primer. The nested primers were situated
on the edge of the VH, VL, or VK region of the immunoglobulin genes
with primers that contain a sequence that overlaps an Ig overlap cassette
system (14). For the VH nested PCR, external (Ext) and internal (Int)
forward primers covered VH1 to VH6 and reverse primers covered IgA,
IgD, IgG, and IgM. For the VK nested PCR, external and internal forward
primers coveredVK1 toVK7 and reverse primers covered the kappa chain
constant (IgK). For the VL nested PCR, external and internal forward
primers covered VL1 to VL10 and reverse primers covered the lambda
chain constant (IgL). The internal primers for VH, VK, or VL had a 5= tag
overlapping the linear cassette fragments expressing the leader sequence
(C fragment), the IgG1 constant region (H fragment), the IgK constant
region (K fragment), or the IgL constant region (L fragment) for overlap-
ping PCR to construct the linear expression cassettes (14).
The nested PCR utilized Qiagen’s HotStarTaq Plus kit. The first PCR
used 5l of the RT product and followed themanufacturer’s instructions
with the addition ofMgCl2. The second PCR used 2.5l of the product of
TABLE 1 Characteristics of hMAbs from volunteers in the DP6-001 trial
Volunteer hMAb Wk Epitope
Heavy chain Light chain
Germ line Mutation % CDR3 Germ line (chaina) Mutation % CDR3
ABL-034 (group A) HH1G9 36 C2/C5 1-2*02 3 16 2-28*01 (K) 1 9
HH2D11 36 NDb 1-2*02 3 19 3-11*01 (K) 0 8
HH4E4 36 ND 1-46*01 5 18 7-43*01 (L) 2 11
ABL-001 (group B) GB1 30 C2 1-69*9 6 18 1-5*03 (K) 4 6
EA1 32 C5 1-69*01 2 19 3-10*01 (K) 1 11
EA7 32 ND 1-69*01 5 14 3-19*01 (L) 4 11
EA8 32 ND 4-39*01 9 20 1-40*01 (L) 3 11
ABL-003 (group B) CC3C2 36 ND 3-30*03 2 23 1-44*01 (L) 2 11
CC6B5 36 C2 1-46*01 3 12 1-26*01 (K) 4 9
CC6C11 36 ND 1-46*01 5 12 1D-17*02 (K) 1 9
ABL-040 (group C) TA6 30 V3 1-3*01 5 18 3-10*01 (L) 3 11
TA7 30 V3 1-3*01 4 17 3-10*01 (L) 1 11
TB7 30 C2/C5 1-69*06 2 23 2-14*01 (L) 2 10
a K, kappa chain; L, lambda chain.
b ND, not determined.
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the first PCR and replaced MgCl2 with Qiagen Q buffer in the reaction
mixture. The PCR products were then cleaned up with a Qiagen PCR
cleanup kit for sequencing analysis.
The variable region sequence from heavy and light chain cloning was
analyzed by the IMGT/V-QUEST software program (15). Parameters that
were collected included the functionality of the sequence; the heavy,
kappa, or lambda chain designation; the allele designation for V, D, and J;
CDR (complementarity-determining region) and FR (fragment region)
lengths; percent identity to the germ line; and the junction amino acid
sequence.
Construction of linear Ig expression cassettes.After identification of
400- to 500-bp bands from RT-PCR, sequencing was done with primer
CL-F681 (TCTGGGTTCCAGGTTCCACTGGTGAC) to confirm that the
Ig sequence was functional. After sequence verification, variable region
fragments were cloned into an immunoglobulin-expressing linear cas-
sette by overlapping PCR (14). The 5= fragment of the cassette contained
a cytomegalovirus promoter and an Ig leader sequence, while the IgH,
IgK, or IgL 3= fragment contained the constant region of the Ig heavy chain
(IgG1), kappa chain, or lambda chain, respectively, and a polyadenylation
signal. The overlap PCRwas donewith iProofDNApolymerase (Bio-Rad,
FIG 2 Reactivities of 13 hMAbs against a panel of five autologous gp120 proteins included in the DP6-001 trial measured by ELISA. HIV-1 Env gp120 proteins
were derived from the following isolates: 92UG037.8 (A2), 92US715.6 (B), Ba-L (Bal), 96ZM651 (Czm), and 93TH976.17 (AE). (A) hMAbs from one group A
volunteer; (B) hMAbs from two group B volunteers; (C) hMAbs from one group C volunteer; (D) well-characterized hMAbs as controls. OD450 nm, optical
density at 450 nm.
Fc Receptor-Mediated Activities of HIV Vaccinee MAbs
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CA) according to the manufacturer’s instructions. Equal amounts of the
VH, VK, or VL PCR product, 5= promoter region fragment, and the 3=
constant region CH, CK, or CL fragment were mixed with deoxynucleo-
side triphosphates, HF buffer, forward and reverse primers, and iProof
DNA polymerase (Bio-Rad, CA). After the overlap PCR product of the
heavy, kappa, or lambda chain was verified by agarose gel electrophoresis,
the paired IgH/IgK or IgH/IgL fragments were used for transient transfec-
tion of 293T cells to produce antibodies in the transfection supernatant.
The supernatant was used for screening for gp120 binding by ELISA, as
described below. Clones of interest were further cloned into amammalian
expression vector, pJW4303, for large-scale production.
Expression and production of recombinant MAbs. For large-scale
production, equal copy numbers of heavy and light chain plasmids were
transfected with polyethyleneimine into Freestyle 293F cells (Invitrogen).
After 2 days of expression, the cell culture supernatant was harvested and
human IgG was purified by Äkta fast-performance liquid chromatogra-
phy with protein A HP columns (GE Healthcare).
HIV-1 gp120 protein production and conjugation. Recombinant
HIV-1 gp120 was produced from transient transfection of Freestyle
293F cells. Plasmids expressing the gp120 proteins from HIV-1 strains
92UG037.8 (A2), 92US715.6 (B), Ba-L (Bal), 96ZM651 (Czm),
93TH976.17 (AE), JR-FL, 93MW965 (C2), 92UG021 (D), and consensus
FIG 3 Reactivities of 13 hMAbs against a panel of heterologous gp120 proteins revealed by ELISA. HIV-1 Env gp120 proteins were derived from the following
isolates: JR-FL, 93MW965 (C2), 92UG021 (D), and consensus clade AE (AE Con). (A) hMAbs from one group A volunteer; (B) hMAbs from two group B
volunteers; (C) hMAbs from one group C volunteer; (D) well-characterized hMAbs as controls.
Costa et al.
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AE sequences were used to transfect 293F cells by use of the 293Fectin
transfection reagent (Invitrogen), and after 2 days of expression, the cell
culture supernatant was harvested and the gp120 protein was purified
over a lectin column.
Biotinylation was performed by transferring biotin to the lysine resi-
due in the Avitag sequence (LNDIFEAQKIEWHE) at the C terminus of
gp120. A commercially available biotin ligase system (Avidity, CO) was
used to biotinylate the Avitag sequence of theDP6-001 autologous gp120s
(from strains A2, B, Bal, Czm, and AE). The biotinylated gp120 proteins
were then further conjugated to streptavidin-APC (Invitrogen) or Extr-
Avidin reagent-PE (Sigma) as previously reported (14, 16).
ELISA. Supernatant from the B cell clonal culture, supernatant from
cultures of 293T cells transiently transfected with paired IgH/IgK or IgH/
IgL linear cassettes, or purified MAb was screened for binding in a sand-
wich ELISA format in 384-well microtiter plates (Corning, NY). First, 20
l/well of goat anti-human IgG Fc (catalog no. 2048-01; Southern Bio-
tech) in phosphate-buffered saline (PBS; 1 g/ml) was incubated over-
night at 4°C. Then, the plate was blocked for 1 h at 37°C in 40 l/well of
blocking buffer (PBS containing 4% whey and 5% powdered milk). The
plates were further incubated with 20-l/well serial dilutions of antibody
in dilution buffer (PBS containing 4%whey) for 1 h at room temperature.
Biotinylated gp120 or peptide (20 l/well) at 1 g/ml in dilution buffer
was incubated for 1 h at room temperature. Streptavidin-conjugated
horseradish peroxidase (Vector Laboratories, CA) was diluted in dilution
buffer to 500 ng/ml, added to the plate, and incubated for 1 h at room
temperature. The plates were washed five times with wash buffer (PBS
containing 0.1% Triton-X) between steps. In the last step, the plates were
developed for 5 min at 37°C in 20 l of a 3,3=5,5=-tetramethylbenzidine
substrate solution (Sigma). The reaction was stopped with 20 l of 2 N
H2SO4. The plates were read at 450 nm.
For testing the breadth of binding in the ELISA, a concanavalin A
(ConA) ELISA format was utilized. In 384-well microtiter plates (Corn-
ing, NY), 20l of ConA (5g/ml in PBS) was incubated at room temper-
ature for 1 h. Then, 20 l gp120 (1 g/ml) was added and the plates were
incubated overnight at 4°C. After blocking for 1 h at 37°C in blocking
buffer, serial dilutions of MAbs diluted in dilution buffer were added to
the wells and the plates were incubated for 1 h at room temperature.
Biotinylated goat anti-human IgG (H/L; Vector Laboratories) was diluted
in dilution buffer to 1 g/ml and added to the wells, and the plates were
incubated for 1 h at room temperature. Streptavidin-conjugated horse-
radish peroxidase (Vector Laboratories) was diluted in dilution buffer to
500 ng/ml and added to the plate, and the plate was incubated for 1 h at
room temperature. The plates were washed five times with wash buffer
(PBS containing 0.1% Triton-X) between steps. Finally, the plates were
developed for 3 min at room temperature in 20 l of a 3,3=5,5=-tetram-
ethylbenzidine substrate solution (Sigma). The reaction was stopped with
20 l of 2 N H2SO4. The plates were read at 450 nm.
Measurement of binding affinitywith anOctetQke instrument.The
kinetics of human MAb binding to gp120 proteins were measured on an
Octet Qke instrument (manufactured by ForteBio), based on biolayer
interferometry. The antibody being tested was loaded onto protein A sen-
sor tips diluted to 10 g/ml in ForteBio kinetics buffer. After capture, the
tips were washed in kinetics buffer and a baseline measurement was re-
corded. The tipswere then incubated inwells containing serial dilutions of
gp120 protein (300 nM to 0.4 nM) to measure the association rate (Kon)
and dissociation rate (Koff). The antibody binding kinetics and equilib-
rium dissociation constant (KD; Koff/Kon) values were analyzed by the
ForteBio Data Analysis software package (version 7.1) using a 1:1 binding
model.
Neutralization assays. Pseudovirus neutralization assays were per-
formed using a system previously optimized in TZM-bl cells (17). Pseu-
dovirus was generated by cotransfection of a gp160 envelope with the
pSG3Env backbone. Pseudotyped virus was added at 200 tissue culture
infective doses per well and incubated with antibody at 37°C for 1 h.
TZM-bl cells were then seeded at 10,000 cells/well in DEAE-dextran at a
final concentration of 20 g/ml. The plates were incubated at 37°C for 48
h and then developed with a luciferase assay reagent per the manufactur-
er’s instructions (Promega). The numbers of relative light units (RLUs)
were collected by running of the plates on a Wallac luminometer. Neu-
tralization was calculated as the percent reduction in luciferase activity in
the presence of antibody compared to the luciferase activity induced by
the virus control without antibody, calculated as follows: {[1  (average
number of sample RLUs  number of cell control RLUs)/(number of
virus control RLUs number of cell control RLUs)]} 100.
TABLE 2 Kinetics of binding of DP6-001 hMAbsa
a NB, no binding; KD, equilibrium dissociation constant (M); red, equilibrium dissociation constants of
1.0E10; brown, equilibrium dissociation constants of 1.0E9 to 1.0E10; orange, equilibrium dissociation
constants of 1.0E8 to 1.0E9; yellow, equilibrium dissociation constants of	1.0E8.
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ADCC assays. (i) ADCC against gp120-coated target cells. The
GranToxiLux (GTL) assay was used to detect the ADCC activities of hu-
man MAbs and plasma directed against CEM.NKRCCR5 cells (NIH AIDS
Reagent Program,Division of AIDS) coatedwith recombinant gp120 pro-
teins (from strain A2, B, Bal, Czm, or AE) which were included as part of
the vaccine immunogens as described previously (18). Cryopreserved hu-
man PBMCs from an HIV-seronegative donor with the homozygous
158V/V genotype for Fc gamma receptor IIIa were used as the source of
effector cells (19) at an effector-to-target cell ratio of 30:1. Data are re-
ported as the proportion of cells positive for proteolytically active gran-
zyme B (GzB) out of the total viable target cell population (percent GzB
activity) after subtraction of the background activity observed in wells
containing effector and target cells in the absence of antibodies or plasma.
ADCC endpoint titers were determined by interpolation of the dilutions
FIG 4 Multiple epitopes elicited by vaccination in human volunteers revealed by use of a peptide microarray. Purified hMAbs were tested on JPT Peptide
Technologies slides containing overlapping peptides for a diverse set of gp120s frommultiple clades (identified on the right), including consensus sequences. (A)
Peptide microarray against multiple gp120 protein peptides, focused on epitopes in clades C2, C5, and V3. The numbers on the x axes of panel A are amino acid
positions. (B) ELISA against a consensus clade B V3 circular peptide.
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of sera that intercepted the positive cutoff (8%GzB activity) using Graph-
Pad Prism (version 6.0) software (GraphPad Software, Inc.).
(ii) ADCC against HIV-1-infected target cells. The ability of DP6-
001 hMAbs and plasma to direct the killing of CEM.NKRCCR5 cells
infected with subtype AE HIV-1 isolate CM235 (GenBank accession
no. AF259954.1; Agnès Chenine, U.S. Military HIV Research Program)
and subtype B isolate Bal (GenBank accession no. AY426110) infectious
molecular clone (IMC) viruses containing a Renilla luciferase (Luc) re-
porter gene (20) was measured using a Luc-based ADCC assay according
to a previously described procedure (21, 22). Cryopreserved PBMCs were
used as a source of effector cells (effector-to-target cell ratio, 30:1). Killing
was measured as a reduction in luminescence (ViviRen assay; Promega)
compared to that of control wells containing target and effector cells in the
absence of antibodies. ADCC endpoint titers were determined by inter-
polating the concentrations of serum that intercepted the positive cutoff
(15% specific killing).
ADCPassays.ADCPwasmeasured by amodified formof a previously
describedmethod (23). Biotinylated gp120 (5g)was incubatedwith 1l
streptavidin-fluorescent beads (FluoSpheres NeutrAvidin-labeled micro-
spheres, 1.0 m, yellow-green fluorescent [505/515 nm], 1% solids; In-
vitrogen) that were diluted 100-fold for 25 min at room temperature in
the dark. THP-1 cells were plated in a 96-well U-bottom plate (250,000
cells per well), and serial dilutions of the MAbs were added. The bead-
gp120mix was then further diluted 5-fold in PBS-bovine serum albumin,
50l of this mixture was added to cells, the cells were incubated for 3 h at
37°C and washed at low speed. The cells were then assayed for fluorescent
bead uptake by flow cytometry using a BDBiosciences LSR II flow cytom-
eter. The phagocytic score was obtained by the formula (percent phago-
cytosis/mean fluorescence intensity) and normalized by division by 106.
RESULTS
Volunteers receiving theDP6-001 vaccine and their serumanti-
body responses. In the current study, a total of 13 human Env-
specificMAbs from fourDP6-001 volunteers (ABL-001, ABL-003,
ABL-034, and ABL-040) were produced by the single B cell clon-
ing approach (Fig. 1). In the DP6-001 trial, volunteers in groups A
and B first received three low-dose DNA prime immunizations by
the intradermal (i.d.) and intramuscular (i.m.) routes (1.2 mg
each time), respectively, with a polyvalent formulation including
five gp120-expressing plasmids and one Gag-expressing DNA
plasmid, followed by two immunizations with a polyvalent prep-
aration of five gp120 proteins produced from CHO cells formu-
lated with the adjuvant QS-21 (12). Group C volunteers received
the same formulation, except that they received (i) a higher-dose
DNA prime immunization by the i.m. route (7.2 mg each time)
and (ii) only a single gp120 protein boost immunization due to the
early stop of the clinical trial in this group of volunteers (13). In
TABLE 3 Neutralization titers of hMAb TA6 by TZM-bl cell assaya
Study location, neutralization result, and virus Clade IC50 (g/ml)
UMass
Positive neutralization
MN B 27.5
SF162 B 3.67
SS1196 B 2.23
QH0692.42 B 31.8
Negative neutralization
NL4-3 B 	50
SC422661 B 	50
WITO4160 B 	100
ZM109F.PB4 C 	50
Du156 C 	50
Du422.1 C 	100
ZM197.pB7 C 	50
CM235.c11 CRF01_AE 	50
816367.CO2 CRF01_AE 	50
MLV 	50
Harvard
Positive neutralization
SS1196.1 B 30.08
T271-11 CRF02_AG 59.08
Negative neutralization
MS208.A1 A 	100
Q23.17 A 	100
MN-3 B 	100
SF162.LS B 	100
BaL.26 B 	100
6535.3 B 	100
MW965.26 C 	100
TV1.21 C 	100
ZM109F.PB4 C 	100
DJ263.8 CRF02_AG 	100
242-14 CRF02_AG 	100
TH023.6 CRF01_AE 	100
a IC50, 50% inhibitory concentration; UMass, University of Massachusetts Medical
School; Harvard, Harvard Medical School; MLV, murine leukemia virus.
FIG5 Titers of ADCC activity in serum against gp120-coated cells for select volunteers from aGranToxiLuxADCC assay (A) and infected cells from a Luc-based
ADCC assay (B).
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the current pilot study, MAbs were generated from one group A
volunteer, two group B volunteers, and one group C volunteer
(Fig. 1; Table 1).
Initial DNA priming immunization did not elicit a detectable
gp120-specific IgG titer in these volunteers’ sera, with the excep-
tion of that from the volunteer in group C who received the high-
er-doseDNAprime.However, after the first protein boost, gp120-
specific IgG responses were observed to rise quickly to high titers
(Fig. 1A). Serum neutralization was tested against a diverse panel
of pseudotyped viruses from multiple clades (clades A, B, C, D,
andAE). For the volunteers included in the current study, positive
neutralization activity against this panel of pseudotyped viruses
could be seen in immune sera after one or two protein boost
immunizations, with the titers for the 50% inhibitory dose (ID50)
ranging from 1:20 to 1:977 (Fig. 1B).
HIV-1 Env-specific hMAbs from DP6-001 trial volunteers.
Frozen PBMCs from the four DP6-001 vaccine trial volunteers
were used for antigen-specific cloning of human monoclonal an-
tibodies (hMAbs). The 13 hMAbs in this panel were from single B
cells isolated from frozen PBMCs collected at 30 to 36 weeks after
the initial DNA immunization (i.e., after one or two protein im-
munizations). Immunogenetics analysis showed that except for
FIG 6 ADCC reactivities of 13 hMAbs with a panel of DP6-001 gp120 proteins. HIV-1 Env gp120 proteins were derived from the following isolates: 92UG037.8
(A2), 92US715.6 (B), Ba-L (Bal), 96ZM651 (Czm), and 93TH976.17 (AE). (A) hMAbs from volunteer ABL-034 (group A); (B) hMAbs from volunteer ABL-001
(group B); (C) hMAbs from volunteer ABL-003 (group B); (D) hMAbs from volunteer ABL-040 (group C); (E) hMAb controls.
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two Ig HC variable regions (IGHV) (hMAb CC3C2 and EA8),
which were subtypes 3 and 4, respectively, the IGHVs of these
MAbs were from germ line subtype 1, while the Ig LC variable
regions (IGLVs) weremore diverse, with a variety of variable gene
subgroups being utilized. Themutation rates of IGHVs fromgerm
lines were low, usually 3 to 6%, but the mutation rate for one was
9%. TheCDR3 length ranged from12 to 23 amino acids (Table 1).
Because the volunteers from whom the gp120-specific hMAbs
were isolated were immunized with a polyvalent gp120 vaccine, a
wide selection of gp120 antigens was used to test the breadth of
binding of this panel of MAbs. Two patterns of binding were evi-
dent, with one group of hMAbs broadly binding tomultiple clades
of gp120 proteins and the second group specifically binding to
gp120 antigens from B clade. Nine hMAbs (hMAbs HH1G9,
HH2D11, andHH4E4 from volunteer ABL-034 of groupA;MAbs
GB1, EA7, and EA8 from volunteer ABL-001 of group B; MAbs
CC6B5 and CC6C11 from volunteer ABL-003 of group B; and
MAb TB7 from volunteer ABL-040 of group C) belonged to the
first pattern, although some of them had higher relative binding
than the other hMAbs. Four hMAbs (hMAb EA1 from volunteer
ABL-001 of group B, hMAb CC3C2 from volunteer ABL-003 of
group B, and hMAbs TA6 and TA7 from volunteer ABL-040 of
group C) belonged to the second pattern. This pattern was con-
sistent between the gp120 antigens autologous to vaccine compo-
nents used in the ELISA (Fig. 2) and the gp120 antigens heterolo-
gous to gp120 vaccine components used in the ELISA (Fig. 3).
Those hMAbs with broad reactivity against autologous gp120 an-
tigens were also able to recognize a wide range of heterologous
gp120 antigens. One noticeable exception was the gp120 antigen
from a subtype D virus. Given the fact that the gene sequences of
subtype D viruses are more different from the consensus se-
quences than the gene sequences of viruses of other major sub-
types (such as subtypes A, B, C, and AE), it is not surprising that
the broadly reactive hMAbs cannot recognize the subtype D
gp120. In addition, no gp120 immunogen from subtype D was
included in the vaccine formulation. However, one broadly reac-
tive hMAb, hMAb HH1G9 (from group A), was able to bind all
gp120 antigens tested, including the one from subtype D.
Several human bnAbs well characterized by researchers in the
HIV field were included as controls in the binding antibody anal-
ysis. MAb VRC01 is able to bind to gp120 proteins from different
subtypes but binds less well to the gp120 protein from subtype D.
MAbPGT128 can bind strongly only to gp120 from subtypeA and
binds less well to gp120 proteins fromother subtypes, reflecting its
overall reduced binding to gp120 monomers. Not surprisingly,
V3-specific hMAb 447-52Dmainly binds to subtype B gp120 pro-
teins, confirming its preferred subtype specificity. In contrast,
MAb A32 is able to bind to all gp120 proteins except the one from
subtype D, which may also explain its high ADCC activity against
a wide range of HIV-1 isolates of different subtypes.
The kinetics of binding, including affinities for the panel of
hMAbs from volunteers in the DP6-001 trial, to the same autolo-
gous gp120 proteins used in the ELISA were also measured (Table
2; Fig. 2). The levels of binding affinity are comparable to the
binding profile seen in the ELISA. A few hMAbs that were
subtype B specific (hMAbs EA1 and CC3C2) could also be seen
(Table 2).
Using a peptidemicroarray system (JPT Peptide Technologies,
FIG 7 ADCC activity of humanMAbs. (A) Themaximumpercent GzB activity of 13 hMAbs with a panel of DP6-001 gp120 proteins. HIV-1 Env gp120 proteins
were derived from the following isolates: 92UG037.8 (A2), 92US715.6 (B), Ba-L (Bal), 96ZM651 (Czm), and 93TH976.17 (AE). (B) Maximum percent specific
killing of 11 hMAbs with cells infected with IMC viruses Bal and CM235.
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FIG 8 Plasma ADCP response of MAbs from four DP6-001 trial volunteers against gp120-coated fluorescent beads. (A) Representative histograms of ADCP
assay. Results for Bal gp120-coated fluorescent beads assayed with THP-1 cells using prebleed (day 0) and day 210 sera from volunteer ABL-001 as examples are
shown. Bars indicate percent positive cell population bracketed by the horizontal bar. (B)ADCPwith sera fromday 0 andday 210 bleeds from4 volunteers against
beads coated with the following gp120 isolates: 92UG037.8 (A2), 92US715.6 (B), Ba-L (Bal), 96ZM651 (Czm), and 93TH976.17 (AE).
Costa et al.
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Berlin, Germany), linear epitopes were determined for about half
of the hMAbs from volunteers in the DP6-001 trial included in
this study (Table 1). The other half did not give clear dominant
binding peaks, indicating that their epitopes may be conforma-
tional. The linear epitopes were mainly in the constant regions,
including C2 (hMAbs GB1 and CC6C11), C5 (hMAb EA1), and
C2/C5 (hMAbs HH1G9 and TB7) (Table 1). Representative JPT
Peptide Technologies mapping results are shown in Fig. 4A. Two
hMAbs from the DP6-001 trial (TA6 and TA7) had specific bind-
ing to peptides in the V3 region (Table 1). For the V3-specific
hMAbs, a peptide ELISA using cyclic V3 was further used to con-
firm TA6 and TA7 binding, along with positive-control V3-spe-
cific MAb 447-52D and negative-control non-V3-specific hMAb
EA1 and TB7 binding (Fig. 4B).
Themajorityof clonedDP6-001hMAbsdidnot exhibit aneutral-
ization titer, with the exception of the V3-specific hMAbTA6, which
could weakly neutralize tier 1 subtype B pseudoviruses based on the
neutralization assay conducted in-house at the University of Massa-
chusetts Medical School or at M. Seaman’s laboratory (Table 3).
ADCCactivitieswith sera andhMAbs fromvolunteers in the
DP6-001 trial. We next studied the presence and levels of Fc-
mediated antibody activities in either immune sera or hMAbs
from volunteers in the DP6-001 trial (Fig. 5 and 6). After multiple
immunizations, including a protein boost, gp120-specific ADCC
FIG 9 ADCP reactivity of 13 hMAbs with a panel of DP6-001 gp120 proteins. HIV-1 Env gp120 proteins were derived from the following isolates: 92UG037.8
(A2), 92US715.6 (B), Ba-L (Bal), 96ZM651 (Czm), and 93TH976.17 (AE). (A) hMAbs from volunteer ABL-034 (group A); (B) hMAbs from volunteer ABL-001
(group B); (C) hMAbs from volunteer ABL003 (group B); (D) hMAbs from volunteer ABL-040 (group C); (E) normal human Ig (NHIgG) used as a negative
control.
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activities could be seen in all volunteers and were sustained out to
36 weeks, which was the last time point that we included in the
ADCC study. ADCC activity against both subtype B and subtype
AE gp120 antigens was seen (Fig. 5A). Most significantly, ADCC
activities could be detected by using either the assay format with
target cells coated with recombinant gp120 antigens or the infec-
tion format with viruses expressing HIV-1 Env antigens (Fig. 5A
and B). ADCC levels in cells with viruses expressing HIV-1 Bal
Env were lower than those in cells with viruses expressing HIV-1
CM235 (Fig. 5B). The ADCC activities in the serum from volun-
teer ABL-040 (group C of the DP6-001 trial) were lower than
those in the sera from the other three volunteers, most likely due
to the fact that group C volunteers did not receive the second
protein boost (Fig. 5B).
Most of the hMAbs generated by these volunteers in the DP6-
001 trial also showed high levels of ADCC activity (Fig. 6A to D).
The hMAbs that showedbroad gp120 binding activity also showed
broad ADCC activities. Those with narrow binding specificity
(mainly B subtype; hMAbs EA1, CC3C2, TA6, and TA7) also had
poor ADCC activity. TB7 was the one hMAb that had a broad
gp120 binding profile but lackedADCCactivity, indicating that all
hMAbs produced from this group C volunteer had poor ADCC
activity (Fig. 6D). When the relative ADCC activities were com-
pared with the activity of the positive-control hMAbA32, some of
the hMAbs from the volunteers in the DP6-001 trial (MAbs GB1,
EA7, andCC685) hadADCCactivities against selected subtypes of
gp120 antigens close to the ADCC activity achieved by A32 (Fig.
6E and 7A). The hMAbs from the DP6-001 trial were also tested
against cells infected with two infectious molecular clone (IMC)
viruses, Bal and CM235. The levels of specific killing were lower
than those seen with gp120-coated cells, though hMAb GB1 was
still able to mediate decent ADCC activity against both IMC vi-
ruses (Fig. 7B).
Another important Fc-mediated function that was explored in
the current study was antibody-dependent cellular phagocytosis
(ADCP). As seen with the antibody binding and ADCC analyses,
sera from the volunteers in the DP6-001 trial were able tomediate
ADCP against all 5 autologous gp120 proteins (Fig. 8). Also con-
sistent with the ADCC results was the observation that group C
volunteer ABL-040 has reduced ADCP activity, most likely due to
the missing second protein boost in the original human vaccine
study (12).
Themajority of hMAbs from theDP6-001 trial were capable of
mediating ADCP against the entire range of vaccine autologous
gp120 antigens. Like the results of the ADCC study, two hMAbs
with narrow gp120 binding (hMAbs EA1 and CC3C2) also had
lower levels of ADCP activity. Also similar to the ADCC results,
while hMAb TB7 had a relatively broad binding antibody profile,
its ADCP activitywas also low. Interestingly, hMAbsTA6 andTA7
still showed strong ADCP activity against multiple subtypes of
gp120 antigens, even though they had narrow binding breadths
and low levels of ADCC activity (Fig. 9).
When the endpoint titer for ADCP or the maximum ADCP
score was used, hMAbs from volunteers in the DP6-001 trial
showed quite impressive ADCP activities (Fig. 10). They were
even higher than the ADCP activity of hMAbA32, which is known
for having extremely highADCCactivity againstmany subtypes of
gp120 antigens. In contrast, hMAbs VRC01 and PGT128 showed
higher ADCP activities than hMAb A32.
In summary, it can be seen that the antibody binding profiles
and the ADCP activities of the hMAbs from volunteers in the
DP6-001 trial are the factors that most closely correlate (Table 4).
The broad gp120 binding reactivity was mirrored by the ADCP
activity. The position where we see ADCC activity drop off is with
the MAbs that have B clade-specific gp120 binding (hMAbs EA1,
CC3C2, TA6, and TA7). Two B clade-specific MAbs, EA1 and
CC3C2, had low to no ADCC activity against gp120 from any
clade, including subtype B ADCC targets. The one exception to
this was hMAb TB7, which had moderate but broad gp120 bind-
ing activity but no ADCC activity (Table 4).
DISCUSSION
Analysis of nonneutralizing antibody responses in immune sera
from volunteers in the RV144 trial showed that ADCC was a cor-
relate of reduced infection risk in the groupwith low IgAC1 bind-
ing titers (1). At the same time, knowledge in this area is limited
due to the limited availability of human MAbs that are generated
from non-HIV-infected individuals. More studies are needed to
understand Fc effector functions in the responses of antibodies
from volunteers who received different experimental HIV vac-
cines.
The current study produced another panel of human Env-spe-
cific MAbs from a vaccine trial in healthy volunteers. While these
MAbs, with the exception of TA6, did not exhibit significant neu-
FIG 10 Themaximum (Max) ADCP reactivity of 13 hMAbswith a panel of DP6-001 gp120 proteins. HIV-1 Env gp120 proteins were derived from the following
isolates: 92UG037.8 (A2), 92US715.6 (B), Ba-L (Bal), 96ZM651 (Czm), and 93TH976.17 (AE). Normal human Ig (NHIgG) was used as a negative control.
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tralization activity, they did display a broad breadth of gp120
binding, along with substantial Fc-mediated effector activity of
similar breadths against various subtypes of HIV-1. Multiple lin-
ear epitopes along with some potential conformational
epitopes contributed to the activities present in this newest panel
of vaccine-elicited hMAbs. One such region could be classified as
being adjacent to the epitope for cluster A antibodies to which
nonneutralizing monoclonal antibodies such as C11 belong. The
activity directed against the cluster A region was associated with a
reduced risk of infection in the RV144 trial. This region has pre-
viously been shown to be a target of ADCC-mediated viral escape
(24–26). hMAbs HH1G9, EA1, and TB7 all have an epitope that is
adjacent to the cluster A epitope.
One of the central activities that was associatedwith protection
in the RV144 trial was ADCC. The panel of MAbs isolated from
volunteers vaccinated in the RV144 trial lacked neutralization ac-
tivity but had a significant level of ADCC activity against autolo-
gous antigen (27). This pattern was also observed among MAbs
characterized in the current study. Another similarity between
MAbs from the RV144 and DP6-001 trials was that both panels
preferentially used the VH1 germ line locus and recognized mul-
tiple clades, while both sets had a low level of somatic hypermu-
tations (27). Some key differences between the two panels of
MAbs were that the MAbs from the RV144 trial lacked linear
epitopes and had consistent ADCC activity. For the subset of
MAbs obtained in the current study that had the most consistent
TABLE 4 Comparison of relative activity for gp120 ELISA binding and ADCC and ADCP activities among hMAbs induced by DP6-001
Volunteer MAb Function
Activitya for gp120 proteins from the following strains:
A2 B Bal Czm AE
ABL-034 (group A) HH1G9 Binding     
ADCC     
ADCP     
HH2D11 Binding     
ADCC     
ADCP     
HH4E4 Binding     
ADCC     
ADCP     
ABL-001 (group B) GB1 Binding     
ADCC     
ADCP     
EA1 Binding     
ADCC     
ADCP     
EA7 Binding     
ADCC     
ADCP     
EA8 Binding     
ADCC     
ADCP     
ABL003 (group B) CC3C2 Binding     
ADCC     
ADCP     
CC6B5 Binding     
ADCC     
ADCP     
CC6C11 Binding     
ADCC     
ADCP     
ABL040 (group C) TA6 Binding     
ADCC     
ADCP     
TA7 Binding     
ADCC     
ADCP     
TB7 Binding     
ADCC     
ADCP     
a, dissociation complex 50 (DC50) for binding of	5 nM,5% maximum GzB activity for ADCC, and maximum ADCP score of5;, DC50 for binding of 0.5 to 5 nM, 5% to
10% maximum GzB activity for ADCC, and maximum ADCP score of 5 to 10;, DC50 for binding of 0.05 to 0.5 nM, 10% to 15% maximum GzB activity for ADCC, and
maximum ADCP score of 10 to 15;, DC50 for binding of 0.005 to 0.05 nM, 15% to 20% maximum GzB activity for ADCC, and maximum ADCP score of 15 to 20;,
DC50 for binding of0.005 nM,	20% maximum GzB activity for ADCC, and maximum ADCP score of	20.
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ADCC activity, gp120 binding was universally broad and potent,
with potent ADCC being present in the absence of the enhancing
modifications introduced in the Fc region as suggested by Shields
et al. (28). These MAbs recognize a mixture of linear and possible
conformational epitopes. These characteristics are possibly due to
the vaccine formulation utilized in the DP6-001 trial, which in-
cluded a 5-valent gp120 prime and boost, while in the RV144 trial,
only two envelope proteins were included in the vaccine. Al-
though there were other differences between the vaccine formu-
lations, such as a viral vector prime compared to aDNAprime, the
most likely factor involved in the epitope differences would be the
antigens. The one linear epitope seen in the MAbs with ADCC
activity from the RV144 trial was V3 (CH23), whichwas also pres-
ent in our panel (hMAbs TA6 and TA7). Both sets of V3-specific
MAbs were clade specific in their ADCC activities.
A smaller panel of RV144MAbs (MAbs CH58, CH59, HG107,
and HG120) was specifically isolated because of their V2 epitope,
which was correlated with protection in vaccine recipients and
their ability to mediate ADCC against RV144 vaccine strains (1,
22). Like the MAbs from the DP6-001 trial, these MAbs from the
RV144 trial developed from the germ line with a low mutation
rate. In contrast, MAbs from the RV144 trial utilized multiple
immunoglobulin gene families, while the MAbs from the DP6-
001 trial had a VH1 focus. Another difference between the two
panels of MAbs was that the MAbs from the RV144 trial were
specific to the isolates with the conserved critical binding residues
by Liao and collaborators (22) and able to mediate neutralization
against a couple of tier 1 clade AE viruses (22). Epitopes that can
mediate ADCC are diverse, and as seen in the RV144 andDP6-001
trials, vaccines are able to elicit ADCC to multiple epitopes (1, 22,
27, 29). When antibodies against the two regions implicated in
protection in the RV144 trial (C1 and V2) were tested together,
synergy that increased the potency of CH58 to clinically relevant
concentrations was observed (30). Because the epitope and activ-
ity of Fc-mediated functions like ADCC and ADCP are not as
dependent on functional and well-formed trimers, elicitation of
these types of MAbs could be an important component in a suc-
cessful HIV vaccine.
Along with ADCC, another Fc-mediated function that was ex-
plored was ADCP activity. Recent studies have started to look into
comparisons between vaccine trials and the differences in serology
that may help with distinguishing which protocol will be best (9).
With the group of MAbs that displayed the greatest breadth of
gp120 binding and ADCC activity, ADCP activity was also broad
and potent in the current study.Our study is one of the few to start
looking into a more complete description of the Fc-mediated
functions of MAbs elicited by vaccines in humans. Although the
value of nonneutralizing activity is still being explored, some evi-
dence indicates that there is immune pressure that HIV tries to
circumvent during chronic infection. It has been shown that dur-
ing chronic infection, FcRII is downregulated on immune cells,
and this downregulation is specifically associated with a loss of
ADCP activity (5).While groups have compared ADCP activity in
sera, our study is among the first to start to look more specifically
at MAbs (31). Even without neutralization, the ability of MAbs to
broadly bind gp120 was associated with the breadth of ADCP
activity in the current study. This elicitation of multiclade MAbs
may be an important factor to consider in future vaccine design.
Recent studies in macaques have given evidence for this stance.
Utilizing both simian immunodeficiency virus andHIV immuno-
gens, polyfunctional antibody responses and antibody titers were
correlated with increased sterilizing immunity (32). Both the pro-
tocol with macaques and the DP6-001 vaccine regimen utilized a
protein boost. In the study with macaques, the protective efficacy
was linked to the protein boost, which conferred both polyfunc-
tional antibodies and protective efficacy. The groups that lacked a
protein boost had reduced levels of both of these parameters (32).
Therefore, it is exciting to demonstrate in the current report that
broadly cross-reactive and polyfunctional MAbs can indeed be
elicited in healthy human volunteers with the polyvalent DNA
prime-protein boost HIV vaccine formulation DP6-001.
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